目的 探討止痛化癥膠囊聯(lián)合阿莫西林克拉維酸鉀治療慢性盆腔炎的臨床療效。方法 選取2019年8月—2020年8月在河南中醫(yī)藥大學(xué)第三附屬醫(yī)院治療的84例慢性盆腔炎患者，隨機(jī)分為對(duì)照組（42例）和治療組（42例）。對(duì)照組患者口服阿莫西林克拉維酸鉀片，1片/次，2次/d。治療組患者在對(duì)照組基礎(chǔ)上口服止痛化癥膠囊，2～3次/d，4粒/次。兩組患者連續(xù)治療14 d。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀好轉(zhuǎn)時(shí)間，血清白細(xì)胞介素21（IL-21）、白細(xì)胞介素17（IL-17）、C反應(yīng)蛋白（CRP）和腫瘤壞死因子α（TNF-α）水平及不良反應(yīng)情況。結(jié)果 治療后，治療組臨床總有效率明顯高于對(duì)照組率（P<0.05）；治療后，治療組患者下腹疼痛、白帶量多、腰骶疼痛、經(jīng)期量多好轉(zhuǎn)時(shí)間均明顯短于對(duì)照組（P<0.05）。治療后，兩組患者血清IL-21、IL-17、CRP、TNF-α水平均明顯降低（P<0.05），且治療組患者明顯低于對(duì)照組（P<0.05）。治療組不良反應(yīng)發(fā)生率明顯低于對(duì)照組（P<0.05）。結(jié)論 止痛化癥膠囊與阿莫西林克拉維酸鉀片聯(lián)合治療慢性盆腔炎，臨床效果顯著，臨床癥狀改善明顯，機(jī)體免疫功能得到增強(qiáng)，能有效降低炎癥反應(yīng)，且不良反應(yīng)發(fā)生率較低。

Objective To investigate the clinical efficacy of Zhitong Huazheng Capsules combined with amoxicillin and clavulanate potassium in treatment of chronic pelvic inflammatory disease. Methods Patients (84 cases) with chronic pelvic inflammatory disease in the Third Affiliated Hospital of Henan University of Traditional Chinese Medicine from August 2019 to August 2020 were randomly divided into control (42 cases) and treatment (42 cases) groups. Patients in the control group were po administered with Amoxicillin and Clavulanate Potassium Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Zhitong Huazheng Capsules on the basis of the control group, 4 grains/time, 2 — 3 times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the improvement time of clinical symptoms, the serum levels of IL-21, IL-17, CRP and TNF-α, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was significantly higher than that of the control group (P < 0.05). After treatment, the upturn times of lower abdominal pain, excessive leucorrhea, lumbosacral pain and menstrual volume in the treatment group were significantly shorter than that in the >control group (P < 0.05). After treatment, the serum levels of IL-21, IL-17, CRP, and TNF-α in the two groups were significantly decreased (P < 0.05), and which in the treatment group were significantly lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion The combination of Zhitong Huazheng Capsules and Amoxicillin and Clavulanate Potassium Tablets in the treatment of chronic pelvic inflammatory disease has significant clinical effects, significant improvement in clinical symptoms, enhanced immune function, effective reduction of inflammation, and the incidence of adverse reactions is low.

R984

河南省中醫(yī)藥科學(xué)研究專(zhuān)項(xiàng)課題（20-21ZY2016）；全國(guó)中醫(yī)藥創(chuàng)新骨干人才項(xiàng)目[豫衛(wèi)中醫(yī)（2019）1號(hào)